Chengdu Saijing Biomedical Technology Co., Ltd.

In healthy subjects, under fasting/postprandial conditions, the absorption rate and extent of enteric-coated adenosylmethionine butanedisulfonate tablets (trade name: Transmetil; specification: 0.5 g (in terms of adenosylmethionine)) produced by Chengdu Saijing Biopharmaceutical Technology Co., Ltd. (test preparation; specification: 0.5 g (in terms of adenosylmethionine)) were studied using ABBOTT LABORATORIES (M) SDN. BHD as the reference preparation, and the bioequivalence of the test preparation and the reference preparation was evaluated. The safety of the test preparation and the reference preparation in healthy Chinese subjects was observed.

To evaluate the safety and tolerability of CG-7321 in subjects with advanced solid tumors, determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of CG-7321; to evaluate the pharmacokinetic characteristics of CG-7321 in subjects with advanced solid tumors, and preliminarily evaluate the anti-tumor activity of CG-7321 in subjects with advanced solid tumors.

A single-center, randomized, open, two-period crossover, single-dose design was used to compare the differences in absorption extent and absorption rate between ursodeoxycholic acid oral suspension (test preparation T, specification: 250 mg: 5 mL) produced by Jiangsu Yunyang Group Pharmaceutical Co., Ltd. on behalf of Chengdu Saijing Biotechnology Co., Ltd. and ursodeoxycholic acid oral suspension (reference preparation R, trade name: Ursofalk®, specification: 250 mg: 5 mL) produced by Dr. Falk Pharma GmbH under fasting and postprandial administration in healthy Chinese people, and to evaluate the safety of the two preparations.